LV

DRUG11 trials

Sponsors

NSABP Foundation Inc, Sun Yat-sen University, PharmaEngine, National Health Research Institutes, Taiwan, Hebei Medical University Fourth Hospital

Conditions

Advanced Pancreatic Cancer (Part 1)Biliary CancersColorectal CancerEsophageal CancerGastric CancerGastric Cancer in SituMetastatic Colorectal CancerNeuroendocrine Carcinomas (NEC)

Phase 1

A Study of PEP02 in Combination With 5-fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Tumors

CompletedNCT02884128

PharmaEngineSolid Tumor

Start: 2006-01-31End: 2010-07-31Updated: 2016-08-30

Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers

CompletedNCT03162510

National Health Research Institutes, TaiwanBiliary Cancers, Gastric Cancer in Situ, Pancreatic Cancers

Start: 2018-06-26End: 2022-01-31Updated: 2022-04-07

Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer

RecruitingNCT06225622

Shanghai Zhongshan HospitalMetastatic Colorectal Cancer

Start: 2024-03-11End: 2026-05-01Target: 78Updated: 2024-03-19

Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV

RecruitingNCT06782685

Dai, GuanghaiAdvanced Pancreatic Cancer (Part 1)

Start: 2024-06-23End: 2027-03-31Target: 138Updated: 2025-01-20

Phase 2

Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer

WithdrawnNCT01889680

NSABP Foundation IncColorectal Cancer, Metastatic Colorectal Cancer

Start: 2014-11-30End: 2018-05-31Updated: 2014-12-02

Study of S-1 Plus LV for Advanced Gastric Cancer

CompletedNCT02090153

Sun Yat-sen UniversityGastric Cancer

Start: 2011-07-31End: 2014-03-31Updated: 2014-03-18

Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer

RecruitingNCT06184698

Hebei Medical University Fourth HospitalColorectal Cancer

Start: 2024-01-01End: 2027-03-01Target: 173Updated: 2024-10-09

Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX

Not yet recruitingNCT06210360

Changhai HospitalPancreatic Cancer

Start: 2024-02-01End: 2027-04-01Target: 134Updated: 2024-01-18

Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer

RecruitingNCT06341296

West China HospitalMetastatic Colorectal Cancer

Start: 2024-06-30End: 2026-12-31Target: 86Updated: 2024-08-12

Phase 3

Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC

Not yet recruitingNCT06501664

Rui-hua Xu, MD, PhDEsophageal Cancer

Start: 2024-08-01End: 2027-11-30Target: 360Updated: 2024-07-15

Phase 4

A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma

Not yet recruitingNCT07014540

Beijing GoBroad HospitalNeuroendocrine Carcinomas (NEC)

Start: 2025-06-20End: 2027-12-31Target: 45Updated: 2025-06-11

Related Papers

Preoperative NALIRIFOX versus upfront surgery in high-risk resectable pancreatic cancer: A randomized, multi-center trial.

Journal of Clinical Oncology2026-01-10

Phase II study of irinotecan liposome combined with 5-FU/LV + bevacizumab as first-line therapy in metastatic colorectal cancer: An early analysis from the study.

Journal of Clinical Oncology2025-05-28

Liposomal irinotecan + 5-fluorouracil + leucovorin + bevacizumab as second-line therapy in metastatic colorectal cancer (IRIS): A multi-center, single-arm, prospective, phase II study.

Journal of Clinical Oncology2025-01-271 citations

A phase 1 study of biweekly nab-paclitaxel/oxaliplatin/S-1/LV for advanced upper gastrointestinal cancers: TCOG T1216 study

The Oncologist2024-06-21

Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure–safety analyses in patients with metastatic pancreatic cancer

CPT Pharmacometrics & Systems Pharmacology2021-11-0911 citations

Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway

Cancer Chemotherapy and Pharmacology2016-12-026 citations

A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors

BMC Cancer2016-11-2137 citations

Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway.

Journal of Clinical Oncology2015-05-20